Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: () Report Updated: Oct 17, 2016 | Print This Page

Get more stock ratings by Louis Navellier


Rating: Volatility:
Total Grade: Industry:

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patientís own immune system to attack cancer. The companyís products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.